SOUTH SAN FRANCISCO, Calif. and HOUSTON, June 4, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.

SEATTLE, May 31, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that results from its PIX301 phase 3 clinical trial of Pixuvri® (pixantrone) have

SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that it has received conditional marketing authorization

Eleven Bay Area professionals kick-off spirited 10-week competition to raise funds for blood cancer research. SAN FRANCISCO, March 29, 2012

LEAWOOD, Kan., March 27, 2012 /PRNewswire/ -- Approximately every four minutes someone in the United States is diagnosed with some type of blood cancer.